2. Disease Areas
  3. Cancer
  4. Glioma

Glioma

Gliomas are primary brain tumors arising from glial cells, the supportive cells of the central nervous system, and represent the most common type of malignant brain tumor, accounting for approximately 30% of all brain tumors and 80% of malignant ones. Classified by histological grade, gliomas range from low-grade (grade I–II) slow-growing tumors such as pilocytic astrocytomas to highly aggressive grade IV glioblastomas. They commonly occur in the frontal, temporal, parietal, and occipital lobes and can be well-circumscribed or diffusely infiltrative. Genetic alterations, particularly in IDH genes, play a key role in their pathogenesis and metabolic reprogramming, including increased glutamine synthesis. Symptoms result from mass effect and neurological dysfunction, manifesting as headaches, seizures, cognitive decline, and motor or sensory deficits. Treatment typically involves surgical resection followed by radiation and chemotherapy, though outcomes vary significantly with tumor grade, with higher grades associated with poorer prognosis. Brainstem gliomas, such as diffuse intrinsic pontine gliomas (DIPGs), are particularly challenging due to their inoperable location. Despite advances, gliomas remain difficult to treat, underscoring the need for continued research into targeted therapies and improved diagnostic and prognostic markers.

References:

 

Glioma (168):

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-18935
    CBL0137 1197996-80-7 99.73%
    CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis.
    CBL0137
  • HY-14909
    Bardoxolone 218600-44-3 99.50%
    Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma.
    Bardoxolone
  • HY-50722
    NNC 55-0396 357400-13-6 98.43%
    NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396
  • HY-12494
    LDC1267 1361030-48-9 99.64%
    LDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia.
    LDC1267
  • HY-16397
    Phenformin 114-86-3 98.02%
    Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
    Phenformin
  • HY-W035150
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) 578743-87-0 ≥98.0%
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) (Compound 1) is a NHC copper complex and anticancer agent. Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) exhibits cytotoxic activity against breast cancer, lung cancer, melanoma, and glioma cells.
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I)
  • HY-Q66655
    YRDC-IN-1 3120494-74-5
    YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor. YRDC is a key enzyme that catalyzes the formation of N6-threonylcarbamoyladenosine at position 37 of tRNA (t6A37). YRDC-IN-1 selectively inhibits the translation of ANN codon-enriched FABP7, thereby reducing lipid droplet formation, increasing ROS, and reversing the acquired resistance of GBM to Temozolomide (TMZ) (HY-17364). YRDC-IN-1 can be used for the research of glioblastoma.
    YRDC-IN-1
  • HY-W010480
    Toluquinone 553-97-9
    Toluquinone is a Toluquinol analogue. Toluquinone shows lower growth inhibitory activity against a panel of cancer cell lines of breast adenocarcinoma, promyelocytic leukemia, glioblastoma, fibrosarcoma, and colorectal adenocarcinoma than Toluquinol.
    Toluquinone
  • HY-100685
    MS-444 150045-18-4 99.42%
    MS-444 (BE-34776) is a HuR (ELAVL1) inhibitor that blocks the cytoplasmic translocation of HuR and inhibits its dimerization. MS-444 reduces cytoplasmic HuR levels by preventing the binding of HuR to ARE-mRNA, without altering the total expression of HuR. MS-444 induces apoptosis, inhibits cell growth, angiogenesis and invasion, and also regulates immune function and microbiota. MS-444 effectively alters the number, size and invasiveness of tumors in various cancer models. MS-444 is tolerable to intraperitoneal injection in vivo and can be applied to research related to colorectal cancer, familial adenomatous polyposis, colitis-associated cancer and glioblastoma.
    MS-444
  • HY-101374A
    AGN 192403 hydrochloride 1021868-90-5 99.96%
    AGN 192403 (BRD4780) hydrochloride is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 hydrochloride is also a TMED9 inhibitor. AGN 192403 hydrochloride shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 hydrochloride mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 hydrochloride can be used for glioma tumor and neurological diseases research.
    AGN 192403 hydrochloride
  • HY-W011725
    N-6-Methyl-2-deoxyadenosine 2002-35-9 99.83%
    N-6-Methyl-2-deoxyadenosine (m6dA) is an adenine nucleoside analogue. N-6-Methyl-2-deoxyadenosine targets nuclear processes and DNA replication machineries including WER, SATB1, TFAM, Jumu, SSBP1, DNA polymerase η and phage polymerase Gp90 exo−. N-6-Methyl-2-deoxyadenosine acts as a multifunctional epigenetic regulator that modulates transcription, DNA damage response, cell cycle, transposon silencing, stress adaptation, epigenetic crosstalk, and nucleosome organization in both prokaryotes and eukaryotes. N-6-Methyl-2-deoxyadenosine regulates mitochondrial epigenetic inheritance and is required for fear extinction memory in mice. N-6-Methyl-2-deoxyadenosine exhibits dysregulated levels in cancers. N-6-Methyl-2-deoxyadenosine can be used for the research of glioblastoma, triple negative breast cancer, and conditioned fear (fear extinction impairment).
    N-6-Methyl-2-deoxyadenosine
  • HY-N0762
    Isobavachin 31524-62-6 99.88%
    Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
    Isobavachin
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2
  • HY-160972
    MM0299 474255-10-2 98.51%
    MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC50 value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma.
    MM0299
  • HY-N2392
    Kukoamine A 75288-96-9 99.88%
    Kukoamine A, a spermine alkaloid, is an orally active and brain-penetrant component found in the root barks of Lycium chinense (L. chinense) Miller. Kukoamine A inhibits purified Crithidia fasciculata trypanothione reductase and soybean lipoxygenase, activates μ-opioid receptor. Kukoamine A can inhibt cancer cell proliferation, migration and invasion, cause G0/G1 phase cell cycle arrest and induce apoptosis. Kukoamine A exerts neuroprotective effect and can induce autophagy . Kukoamine A inhibits LPS (HY-D1056)-induced NO, ROS, PGE2, TNF-α, IL-1β, IL-6 production and COX-2 activity. Kukoamine A reverses palmitic acid-induced insulin resistance, lipid accumulation, and oxidative stress via downregulation of Srebp-1c. Kukoamine A can be used for the research of cancer, infection, inflammation, metabolic and neurological disease, such as glioblastoma and Parkinson's disease.
    Kukoamine A
  • HY-P990627
    Anti-EphA2 Antibody (1C1) 99.9%
    Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma.
    Anti-EphA2 Antibody (1C1)
  • HY-D1668
    Biotin-11-dCTP 99.1%
    Biotin-11-dCTP is a biotinylated deoxynucleoside triphosphate and an important DNA labeling reagent. In random primer DNA labeling reactions, Biotin-11-dCTP incorporates into newly synthesized DNA strands to generate labeled DNA probes suitable for hybridization applications. In addition, Biotin-11-dCTP can serve as a substrate for terminal deoxynucleotidyl transferase to end-label oligonucleotides for telomere sequence detection, or to label the cut ends of linearized DNA molecules, thereby supporting streptavidin-based electron microscopy analysis. For example, Biotin-11-dCTP can label the cut ends of linearized DNA molecules under the action of dGTP and avian myeloblastosis virus reverse transcriptase.
    Biotin-11-dCTP
  • HY-W019724
    2,2-Dihydroxyacetic acid 563-96-2 98.0%
    2,2-Dihydroxyacetic acid is an endogenous metabolite, which is the monohydrate of Glyoxylic Acid. 2,2-Dihydroxyacetic acid may participate in the microbial glyoxylate cycle, induce an increase in reactive oxygen species, promote cell differentiation, and modify proteins to form advanced glycation end products (AGEs) (HY-NP165). 2,2-Dihydroxyacetic acid is associated with metabolic diseases such as primary hyperoxaluria.
    2,2-Dihydroxyacetic acid
  • HY-179078
    CT-179 1996636-69-1 99.61%
    CT-179 is a brain-penetrant and orally active OLIG2 inhibitor with a human IC50 of 1250 nM. CT-179 disrupts OLIG2 dimerization, phosphorylation, and DNA binding, blocking OLIG2-driven transcription. CT-179 induces G2/M phase arrest and increases G0 population. CT-179 induces apoptosis by reducing anti-apoptotic proteins and increasing cleaved caspase-3 and cleaved PARP. CT-179 can be used for the research of subgroup medulloblastoma.
    CT-179
  • HY-P11099
    Cys-LT7 1254540-73-2 99.90%
    Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma.
    Cys-LT7